BioLineRx Ltd. BLRX
2.60
0.08
3.17%
as of 25 Sep
- Market cap
- $12.6M
- P/E
- 0.0×
Follow BLRX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(21.24%) | (6.38%) | (37.91%) | (38.10%) | |
| (6.43%) | (2.94%) | (19.20%) | (18.21%) | ||
ROIC |
(160.93%) | (56.36%) | (60.18%) | (74.28%) | |
Return on Tangible Assets |
(19.82%) | (10.03%) | (97.52%) | (249.61%) | |
Average Days of Receivables |
20.03 | 141.05 | 492.31 | 190.89 | |
Free Cash Flow per Share |
(3.10) | (1.97) | (1.75) | (2.43) | |
Free Cash Flow |
(13.48) | (8.11) | (7.78) | (10.81) | |
Capital Expenditures |
— | (0.04) | (0.01) | 0.00 | |
Piotroski F-Score |
5.00 | 4.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(24.60%) | (15.19%) | (16.87%) | (29.68%) | |
Accounts Receivable Turnover |
5.47 | 0.54 | 0.74 | 2.76 | |
Accounts Payable Turnover |
0.92 | 0.03 | 0.04 | 0.04 | |
Inventory Turnover |
2.19 | 0.09 | 0.11 | 0.11 | |
Average Days of Payables |
329.25 | 8,309.30 | 8,973.23 | 8,534.17 | |
Days of Inventory on Hand |
126.78 | 3,408.78 | 2,705.52 | 2,845.16 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
59.15% | 685.85% | 641.80% | 690.73% | |
Selling, General and Administrative Expense of Revenue |
72.56% | 266.44% | 214.91% | 263.58% | |
Share Based Compensation of Revenue |
1.52% | 33.56% | 19.97% | 21.98% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
4.53 | 6.87 | 0.98 | 1.55 | |
Depreciation/Fixed assets |
13.76 | 3.27 | 3.05 | 2.68 | |
Capex/Depreciation |
0.00 | (0.07) | (0.03) | (0.01) | |
Revenue per Share |
2.93 | 0.29 | 0.32 | 0.31 | |
Operating CF per Share |
(3.10) | (1.96) | (1.75) | (2.43) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.03 | 0.01 | 0.00 | |
Net Profit Margin |
(23.38%) | (99.58%) | (563.69%) | (502.08%) |
Columns are period end dates